re: Yale Post Vaccination Syndrome Study - the Spike Protein is as Transient as Inflation

quote:

---

Not according to the Yale study.

---

Yes according to the study ... which I suppose you've not yet read.

quote:

---

Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination
Bornali Bhattacharjee, Peiwen Lu, Valter Silva Monteiro, Alexandra Tabachnikova, Kexin Wang, William B. Hooper, Victoria Bastos, Kerrie Greene, Mitsuaki Sawano, Christian Guirgis, Tiffany J. Tzeng, Frederick Warner, Pavlina Baevova, Kathy Kamath, Jack Reifert, Danice Hertz, Brianne Dressen, Laura Tabacof, Jamie Wood, Lily Cooke, Mackenzie Doerstling, Shadan Nolasco, Amer Ahmed, Amy Proal, David Putrino, Leying Guan, Harlan M. Krumholz, Akiko Iwasaki
doi: LINK

This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

SUMMARY
COVID-19 vaccines have prevented millions of COVID-19 deaths. Yet, a small fraction of the population reports a chronic debilitating condition after COVID-19 vaccination, often referred to as post-vaccination syndrome (PVS). To explore potential pathobiological features associated with PVS, we conducted a decentralized, cross-sectional study involving 42 PVS participants and 22 healthy controls enrolled in the Yale LISTEN study. Compared with controls, PVS participants exhibited differences in immune profiles, including reduced circulating memory and effector CD4 T cells (type 1 and type 2) and an increase in TNFa+ CD8 T cells. PVS participants also had lower anti-spike antibody titers, primarily due to fewer vaccine doses. Serological evidence of recent Epstein-Barr virus (EBV) reactivation was observed more frequently in PVS participants. Further, individuals with PVS exhibited elevated levels of circulating spike protein compared to healthy controls. These findings reveal potential immune differences in individuals with PVS that merit further investigation to better understand this condition and inform future research into diagnostic and therapeutic approaches.
...

DISCUSSION
In this study, we examined symptoms and circulating immune factors and cell types associated with chronic illness following COVID-19 vaccination. Post-acute conditions following COVID-19 vaccination have been reported for multiple vaccine platforms including mRNA and adenoviral-vectored vaccines6,7,8,9. We observed that the general health status of the PVS participants was far below the general US population average32 based on the GHVAS scores. The patient-reported outcome scores from the PROMIS29 domains were also indicative of lower quality of life. A large fraction of individuals reported the onset of symptoms to be as early as within one day of COVID-19 vaccination. Compared with controls, participants with PVS had reduced CD4+ T cell subsets in circulation (both Th1 and Th2) and an increased percentage of TNFa+ CD8 T cells. Among cell populations of myeloid origin, cDC2 cells were reduced, and non-classical monocytes were elevated among PVS participants. Lower S-specific IgG levels were observed in PVS mainly due to the limited vaccine doses received. Additionally, serological evidence for recent EBV reactivation was also observed. Using machine learning approaches, we further identified a set of 21 core predictive features of PVS status within the LISTEN PVS cohort with potential for further validation and biomarker identification. Most notably, we found elevated levels of spike (S1 and full-length S) in circulation up to 709 days after vaccination among a subset with PVS, even in those with no evidence of detectable SARS-CoV-2 infection.
...

This study has several limitations. Our small sample size could have affected the robustness of the machine learning approaches and prediction of specific immune features in PVS. Due to the limited sample size, we might have failed to capture small but potentially important immune features associated with PVS. Analysis of autoimmune antibody reactivity was restricted to antigens reported in other autoimmune diseases, limiting the discovery of a broader range of autoantibodies. While we used two independent approaches to ascertain previous infection with SARS-CoV-2, negative results cannot definitively preclude prior infection that occurred in the distant past. Other limitations include the lack of analysis of the host genetics that might account for PVS susceptibility, or any other conditions, such as non-prescription drugs or asymptomatic infection with other pathogens that were not tested in our analysis might have predisposed an individual to develop chronic illness following COVID-19 vaccination. While we observed elevated levels of S1 among those with PVS compared to LC, additional studies with matched patient demographic profiles are necessary to determine whether this represents genuine differences or is simply a result of random variation. Finally, we do not know whether our findings extend beyond COVID-19 vaccination since we did not include PVS following other vaccines.

In summary, by revealing distinct immunological features of PVS, this study helped generate hypotheses regarding the underlying pathobiology of this condition. Understanding such mechanisms will help improve the overall safety profile of COVID-19 vaccines and support public health strategies that maximize vaccine efficacy while minimizing adverse effects. However, this study is early-stage and requires replication and validation. We emphasize the critical task of discerning between meaningful results and random fluctuations in the data. Future work is essential to elucidate these relationships. As the global community continues to navigate the challenges of COVID-19 and long COVID, a deeper understanding of vaccine-related immune responses will be essential in refining vaccination practices and ensuring their long-term success.

LINK

---

Pre-publication, limited cohort, no peer review, T-cell reductions with no mention of AIDS -- literal or otherwise, you're welcome.

2021.

Omg. It’s a preprint!

quote:

---

I understand old people who weren't prior infected, worth risk.

But, people in 40s and below?
Why?

---

Some were forced, under threat of discontinued employment.

And honestly, there was a hell of a propaganda push.

You’re making a distinction without a difference.

Among the patients studied for PVS, the study along with others identified that they are being diagnosed with similar symptoms to HIV patients in that the production of spike proteins long after receiving the vaccine are resulting in a massive suppression of their immune systems similar to HIV in impact.

From an end result standpoint the only difference is the culprit, with HIV being triggered by a virus whereas PVS is a result of the spike protein.

But you presumably already knew that.

quote:

---

and IMO personally, implementing it in the pediatric population under EUA (excepting very rare immunologic cases) was malpractice.

---

Malpractice is too kind.

Perhaps human rights abuse is a more appropriate term?

quote:

---

when the mortality rate approached 70%.

---

quote:

---

What kind of larping bullshite is this?

---

quote:

---

Grinder

---

Iirc, Grinder wanted to kill Trump.

I saw my neighbor not allowed to see his dying wife. Had to look through a window.